
|Videos|December 17, 2014
Providing Optimal Care for Prostate Cancer
Advertisement
Episodes in this series

For High-Definition, Click
In this segment, Gary M. Kirsh, MD, describes his practice’s model of coordinating care of each patient by having physicians provide sub-specialty care. For example, if a patient develops metastases, he may be switched to a different doctor—a specialist in treatment and managing metastases. Sanford J. Siegel, MD, shares that his practice takes a similar approach, but uses physician assistants. He sees the effectiveness of using these physician assistants, who are adept at running clinics in a protocol-driven manner.
Advertisement
Related to this article

Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Long-Term Follow-Up Confirms Tivozanib Monotherapy Efficacy in 2L/3L mRCC
4
Colorectal Cancer Isn't the Only Gastrointestinal Cancer Rising in Young Adults
5









